Metastases to meninges – Diagnostics – Overview of Information and Clinical Research

Diagnosing metastases to meninges requires a combination of imaging and laboratory tests, as cancer cells spreading to the thin layers covering the brain and spinal cord can cause symptoms that overlap with many other conditions. Early and accurate diagnosis is crucial for starting appropriate treatment and maintaining quality of life, though the process can be challenging even for experienced specialists.

Introduction: When to Seek Diagnostic Testing

People who should undergo diagnostics for metastases to meninges are typically those who already have a diagnosis of cancer and begin experiencing new neurological symptoms. This condition, also known as leptomeningeal metastases or carcinomatous meningitis, happens when cancer cells travel from their original location to the delicate membranes surrounding the brain and spinal cord.^[2]

It is advisable to seek diagnostic testing if you have been diagnosed with breast cancer, lung cancer, or melanoma and suddenly develop symptoms such as persistent headaches, confusion, vision problems, or difficulty walking. These three cancer types are the most common sources of leptomeningeal metastases, accounting for the majority of cases.^[3] Between five and ten out of every one hundred people with solid tumors might develop this complication, while those with blood cancers have a slightly higher risk of five to fifteen out of every hundred.^[2]

The importance of timely diagnosis cannot be overstated. Unfortunately, metastases to meninges are often not diagnosed early or are misdiagnosed because the symptoms can be vague and similar to other conditions. This delay can lead to patients receiving treatments that only manage symptoms without addressing the underlying spread of cancer.^[6] If you notice changes in your mental state, new weakness in your legs, problems with bladder or bowel control, or seizures while being treated for cancer, these are warning signs that should prompt immediate medical evaluation.^[2]

Even people who have completed cancer treatment should remain vigilant. Cancer cells can spread to the leptomeninges months or even years after the primary tumor was treated. Anyone with a history of cancer who develops unexplained neurological symptoms should discuss the possibility of leptomeningeal involvement with their doctor.^[4]

⚠️ Important

Suspicion of leptomeningeal metastases should be particularly high if neurological symptoms develop in someone already diagnosed with breast cancer, lung cancer, or melanoma. Early recognition and prompt testing can help prevent permanent neurological damage and preserve quality of life during treatment.^[6]

Classic Diagnostic Methods for Identifying the Disease

Diagnosing metastases to meninges can be quite challenging for healthcare providers, even when they suspect the condition. The disease often requires multiple tests because no single examination provides a definitive answer in all cases. The two most important diagnostic tools are imaging studies, particularly magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis obtained through a procedure called lumbar puncture.^[2]

Magnetic Resonance Imaging (MRI)

An MRI scan is often the first imaging test doctors order when they suspect leptomeningeal metastases. This test uses powerful magnets and radio waves to create detailed pictures of the brain and spinal cord without using radiation. In many cases, metastases to meninges can be seen on an MRI as areas where the cancer has spread to the covering layers of the brain or as thickened meninges that appear abnormal.^[6]

However, MRI scans are not perfect for detecting this condition. The images may appear completely normal in some patients who actually have cancer cells in their cerebrospinal fluid. This happens because the cancer cells might be too small or too scattered to show up on the scan. When an MRI does show abnormalities, doctors look for specific patterns such as enhancement of the meninges, which means the tissue lights up when contrast dye is used, or visible nodules along the brain and spinal cord surfaces.^[2]

Lumbar Puncture and Cerebrospinal Fluid Analysis

The most reliable test for diagnosing metastases to meninges is examination of the cerebrospinal fluid, which is the clear liquid that surrounds the brain and spinal cord. To obtain this fluid, doctors perform a lumbar puncture, also called a spinal tap. During this procedure, a thin needle is inserted into the lower back, in the space between vertebrae in the spine, to collect a small sample of CSF.^[2]

The collected fluid is then sent to a laboratory where specialists examine it under a microscope looking for cancer cells. This examination is called CSF cytology. Finding cancer cells in the cerebrospinal fluid confirms the diagnosis of leptomeningeal metastases. However, this test also has limitations. Sometimes cancer cells are not present in the sample even when the patient has the disease, which is called a false negative result.^[6]

Because of the possibility of missing cancer cells on the first attempt, doctors often need to repeat the lumbar puncture multiple times. Studies have shown that the chance of detecting cancer cells increases with each additional sample. The laboratory also measures other characteristics of the cerebrospinal fluid, such as protein levels, glucose levels, and the number and types of cells present, which can provide additional clues about the disease.^[4]

Additional Imaging Studies

Besides MRI, doctors may use other imaging techniques to evaluate the extent of cancer spread. A computed tomography scan, commonly known as a CT scan, uses X-rays to create cross-sectional images of the body. While CT scans are not as detailed as MRI for viewing the meninges, they can be useful when MRI is not available or when a patient cannot undergo MRI due to certain medical devices like pacemakers.^[4]

Specialized imaging tests that use radioactive tracers, called nuclear medicine scans, are sometimes employed. These tests can help identify areas where cancer cells are particularly active throughout the body, including the meninges and cerebrospinal fluid spaces.^[4]

Neurological Examination

A thorough neurological examination by a doctor is an essential part of the diagnostic process. During this examination, the healthcare provider tests various functions including strength, sensation, coordination, reflexes, vision, and mental status. The pattern of neurological problems can help doctors determine which parts of the nervous system are affected by the cancer. For example, weakness in both legs along with bladder problems suggests involvement of the lower spinal cord, while double vision and facial drooping point to problems at the base of the brain where cranial nerves emerge.^[7]

The neurological examination findings are also important for tracking how the disease progresses and whether treatment is working. Doctors use standardized neurological assessments to compare how patients are doing over time. Worsening of the examination results, along with changes in imaging or cerebrospinal fluid, indicates that the disease is progressing despite treatment.^[12]

Distinguishing from Other Conditions

One of the most challenging aspects of diagnosing metastases to meninges is distinguishing it from other conditions that cause similar symptoms. Infections of the meninges, called meningitis, can cause headaches, confusion, and other neurological problems very similar to those caused by cancer spread. Other conditions that must be ruled out include bleeding around the brain, inflammation of blood vessels, or side effects from cancer treatments themselves.^[4]

Cerebrospinal fluid analysis helps distinguish between these possibilities. In infectious meningitis, the fluid typically contains white blood cells and bacteria or other organisms, whereas in leptomeningeal metastases, cancer cells are the main finding. The specific characteristics of the fluid, such as glucose and protein levels, also differ between these conditions, helping doctors make the correct diagnosis.^[4]

⚠️ Important

It can be difficult to diagnose leptomeningeal metastases because both MRI and cerebrospinal fluid analysis can sometimes appear normal even when the disease is present. This is why doctors may need to repeat tests multiple times and consider the complete picture of symptoms, examination findings, and test results together.^[2]

Diagnostics for Clinical Trial Qualification

When patients with metastases to meninges are being considered for enrollment in clinical trials, they typically undergo additional standardized testing beyond what is used for initial diagnosis. Clinical trials are research studies that test new treatments, and they have specific requirements to ensure that participants are suitable candidates and that results can be properly measured and compared.^[8]

Confirmed Diagnosis Requirements

Most clinical trials for leptomeningeal metastases require participants to have a confirmed diagnosis through cerebrospinal fluid analysis showing the presence of cancer cells. This is often called positive CSF cytology. Some trials may accept patients who have typical findings on MRI imaging even if cancer cells have not been found in the spinal fluid, particularly if multiple lumbar punctures have been performed without finding cells but the clinical picture strongly suggests the disease.^[6]

Trial organizers typically require that the cerebrospinal fluid examination or MRI was performed within a certain timeframe before enrollment, often within two to four weeks. This ensures that the diagnosis is current and that the disease status accurately reflects the patient’s condition at the time they enter the study.^[6]

Performance Status Assessment

Clinical trials usually assess how well patients can perform daily activities using standardized scales. The most common is the Karnofsky Performance Status scale, which rates patients from zero to one hundred based on their ability to carry out normal activities and care for themselves. Another widely used scale is the Eastern Cooperative Oncology Group (ECOG) performance status. These assessments help determine whether patients are healthy enough to tolerate experimental treatments and complete the trial protocol.^[12]

Baseline Neurological Documentation

Before starting any experimental treatment in a clinical trial, doctors perform detailed neurological examinations and document all findings carefully. This baseline assessment serves as a comparison point to measure whether the treatment is helping, having no effect, or causing harm. The evaluation typically includes testing of cognitive function, which means assessing memory, attention, and thinking skills, as well as testing motor function like strength and coordination, and sensory function such as the ability to feel touch and pain.^[12]

Standardized neurological examination protocols ensure that all trial participants are evaluated in the same way, making it possible to compare results across different patients and different treatment centers. This consistency is crucial for determining whether a new treatment actually works.^[8]

Laboratory Testing Standards

Clinical trials typically require blood tests to check various organ functions before a patient can enroll. These tests measure how well the liver and kidneys are working, check blood cell counts, and assess other body chemistry markers. Specific cutoff values are established for each trial. For example, kidney function tests called creatinine clearance must often show that the kidneys are working at a certain minimum level, because many cancer drugs are processed by the kidneys and could be harmful if kidney function is too poor.^[12]

Similarly, liver function tests including measurements of enzymes and bilirubin must fall within acceptable ranges. Blood counts must show adequate numbers of red blood cells, white blood cells, and platelets, as many cancer treatments can affect the bone marrow where these cells are made.^[12]

Imaging Protocol Standardization

Clinical trials often have very specific requirements for how MRI scans must be performed. These protocols specify the types of sequences that must be included, whether contrast dye should be used, and how images should be taken. Standardized imaging allows researchers to accurately compare scans taken at different times and at different medical centers participating in the trial.^[8]

Some trials require that the entire brain and spinal cord be imaged at regular intervals throughout the study, even if the patient’s symptoms are not changing. This helps detect progression of the disease early, even before new symptoms appear. The imaging schedule is usually defined in the trial protocol, with scans performed at specific timepoints such as every six to eight weeks.^[8]

Response Assessment Criteria

Clinical trials use standardized criteria to determine whether treatment is working. For metastases to meninges, response is typically evaluated using three main elements that must all be assessed together. First, the neurological examination must show improvement or at least stability, meaning symptoms and signs are not getting worse. Second, repeat cerebrospinal fluid analysis should show clearing of cancer cells or a reduction in the number of cells present. Third, MRI imaging should demonstrate improvement or stability of any visible abnormalities.^[12]

Progressive disease, which means the cancer is getting worse despite treatment, is defined by worsening of the neurological examination specifically due to leptomeningeal metastases, or by worsening of findings on MRI scans. These standardized definitions ensure that all participating doctors and researchers evaluate treatment effects in the same way.^[12]

Quality of Life Assessments

Many clinical trials include regular assessments of quality of life using standardized questionnaires. These tools ask patients about their symptoms, emotional wellbeing, ability to perform daily activities, and social functioning. Because maintaining quality of life is a major goal of treatment for leptomeningeal metastases, these assessments provide important information about whether experimental treatments are helping patients feel better, even if they don’t cure the disease.^[8]

Questionnaires are typically completed by patients themselves at regular intervals throughout the trial. The results help researchers understand not just whether treatments extend survival, but whether they improve the experience of living with this serious disease.^[8]

Prognosis and Survival Rate

Prognosis

Metastases to meninges is a serious and life-threatening condition with a generally poor outlook. The prognosis depends on several important factors including the type of primary cancer, the extent of disease spread throughout the body, how well the patient can function in daily life, and how quickly treatment is started after diagnosis.^[2]

Certain factors are associated with worse outcomes. Having the disease spread to multiple parts of the nervous system at the same time, rather than just one area, tends to result in shorter survival. People who have significant neurological problems at the time of diagnosis, such as severe weakness or mental changes, generally have poorer outcomes than those whose symptoms are milder. The presence of bulky disease, meaning large visible tumor deposits on imaging scans, is also associated with a less favorable prognosis compared to cases where cancer cells are only found in the cerebrospinal fluid without large masses.^[12]

The status of cancer elsewhere in the body also matters greatly. Patients whose primary cancer is well-controlled with treatment and has not spread extensively to other organs tend to live longer than those with widespread disease throughout the body. This makes sense because people typically die from their overall cancer burden rather than from the leptomeningeal involvement alone.^[4]

The type of primary cancer influences prognosis significantly. Some cancers that have spread to the meninges respond better to available treatments than others. Additionally, the existence of effective targeted therapies for certain cancer types, particularly some lung cancers and breast cancers with specific molecular features, has improved outcomes for those patient groups in recent years.^[2]

Treatment can help control the growth of cancer cells in the meninges and maintain quality of life for a period of time. With newer targeted cancer drugs, some patients with specific types of cancer may experience disease control for possibly more than a year. However, the disease remains incurable with current treatments, and the focus is on extending life while maintaining the best possible quality of life.^[2]

Survival Rate

The survival statistics for metastases to meninges are sobering. Without treatment, patients typically survive only four to six weeks after diagnosis. With treatment, survival is extended but remains limited to three to nine months on average, depending on the type of primary cancer and the specific treatments that can be used.^[6]

These numbers represent averages across many patients, and individual outcomes can vary. Some patients live shorter periods while others survive longer than the average, particularly those who respond well to treatment and whose overall cancer burden is relatively limited. The development of more effective treatments, including new targeted therapies and better supportive care, has gradually improved survival times compared to what was seen in the past.^[3]

It is important to understand that these statistics reflect current knowledge and treatment options. Healthcare providers are continuously working to develop better treatments through clinical trials, which may offer hope for improved outcomes in the future. Each patient’s situation is unique, and doctors consider many factors when discussing prognosis with individual patients and families.^[2]

#1 Clinical Trials Search in Europe